News, reviews and podcasts from annual scientific meetings and symposiums around the world.
Young patients with chronic lymphocytic leukaemia (CLL) can enjoy long remissions on the drug ibrutinib, but must stay on it indefinitely to…
A drug combination can safely prevent transplanted stem cells (graft) from attacking the recipient’s (host)…
Mount Sinai physician-scientists in the USA have found that a novel therapy for the bone…
The Australasian Gastro Intestinal Trails Group (AGITG), held their 23rd Annual Scientific Meeting on 12-15…
In a phase III trial, a combination of ivosidenib and azacitidine was found superior in…
A study of nearly 25,000 young people with ALL reveals significant gaps in survival rates…
Patients receiving the anti-CD38 monoclonal antibody isatuximab in addition to the standard three- component induction…
An interim analysis of the TRANSFORM trial comparing CAR T-cell therapy lisocabtagene maraleucel (liso-cel) to…
The Phase II ZUMA-12 trial expands on the ZUMA-1 findings by evaluating the use of axicabtagene ciloleucel…
Follow-up data from the Phase II ZUMA-5 trial showed a long-term survival benefit with axicabtagene ciloleucel (axi-cel)…